LONDON, Oct 19 (Reuters) - AstraZeneca Plc shares fell more than 3 percent on Friday after the European Patent Office revoked a key patent on its key asthma drug Symbicort. The move puts at risk ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback